Literature DB >> 20335223

The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF.

Sandra L Haberichter1, Ulrich Budde, Tobias Obser, Sonja Schneppenheim, Cornelia Wermes, Reinhard Schneppenheim.   

Abstract

We characterized a consanguineous Turkish family suffering from von Willebrand disease (VWD) with significant mucocutaneous and joint bleeding. The relative reduction of large plasma von Willebrand factor (VWF) multimers and the absent VWF triplet structure was consistent with type 2A (phenotype IIC) VWD. Surprisingly, platelet VWF was completely deficient of multimers beyond the VWF protomer, suggesting defective alpha-granular storage of larger multimers. Patients were nearly unresponsive to desmopressin acetate, consistent with a lack of regulated VWF release from endothelial cell Weibel-Palade bodies, suggesting defective storage also in endothelial cells. We identified an N528S homozygous mutation in the VWF propeptide D2 domain, predicting the introduction of an additional N-glycosylation site at amino acid 526 in close vicinity to a "CGLC" disulphide isomerase consensus sequence. Expression studies in mammalian cells demonstrated that N528S-VWF was neither normally multimerized nor trafficked to storage granules. However, propeptide containing the N528S mutation trafficked normally to storage granules. Our data indicate that the patients' phenotype is the result of defective multimerization, storage, and secretion. In addition, we have identified a potentially novel pathogenic mechanism of VWD, namely a transportation and storage defect of mature VWF due to defective interaction with its transporter, the mutant propeptide.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20335223      PMCID: PMC2881501          DOI: 10.1182/blood-2009-09-244327

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers.

Authors:  R J Wise; D D Pittman; R I Handin; R J Kaufman; S H Orkin
Journal:  Cell       Date:  1988-01-29       Impact factor: 41.582

2.  The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF.

Authors:  Jonathan B Rosenberg; Sandra L Haberichter; Mary A Jozwiak; Elizabeth A Vokac; Philip A Kroner; Scot A Fahs; Yohko Kawai; Robert R Montgomery
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

3.  Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC).

Authors:  Z M Ruggeri; I M Nilsson; R Lombardi; L Holmberg; T S Zimmerman
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

4.  Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.

Authors:  Augusto B Federici; Claudine Mazurier; Erik Berntorp; Christine A Lee; Inge Scharrer; Jenny Goudemand; Stephan Lethagen; Ioana Nitu; Gerard Ludwig; Lysiane Hilbert; Pier M Mannucci
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

5.  Synthesis of von Willebrand factor by cultured human endothelial cells.

Authors:  E A Jaffe; L W Hoyer; R L Nachman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

6.  Critical independent regions in the VWF propeptide and mature VWF that enable normal VWF storage.

Authors:  Sandra L Haberichter; Paula Jacobi; Robert R Montgomery
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

7.  Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes.

Authors:  R Nachman; R Levine; E A Jaffe
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

8.  Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor.

Authors:  Grégoire Michaux; Lindsay J Hewlett; Sarah L Messenger; Anne C Goodeve; Ian R Peake; Martina E Daly; Daniel F Cutler
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

9.  The von Willebrand factor propeptide (VWFpp) traffics an unrelated protein to storage.

Authors:  Sandra L Haberichter; Mary A Jozwiak; Jonathan B Rosenberg; Pamela A Christopherson; Robert R Montgomery
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-06-01       Impact factor: 8.311

10.  Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit.

Authors:  C L Verweij; P J Diergaarde; M Hart; H Pannekoek
Journal:  EMBO J       Date:  1986-08       Impact factor: 11.598

View more
  13 in total

Review 1.  Interpreting functional effects of coding variants: challenges in proteome-scale prediction, annotation and assessment.

Authors:  Khader Shameer; Lokesh P Tripathi; Krishna R Kalari; Joel T Dudley; Ramanathan Sowdhamini
Journal:  Brief Bioinform       Date:  2015-10-22       Impact factor: 11.622

Review 2.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

3.  Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.

Authors:  Paula M Jacobi; Joan Cox Gill; Veronica H Flood; David A Jakab; Kenneth D Friedman; Sandra L Haberichter
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

4.  An Insight into Glyco-Microheterogeneity of Plasma von Willebrand Factor by Mass Spectrometry.

Authors:  Ebtesam A Gashash; Arya Aloor; Dong Li; He Zhu; Xiao-Qian Xu; Cong Xiao; Junping Zhang; Aishwarya Parameswaran; Jing Song; Cheng Ma; Weidong Xiao; Peng George Wang
Journal:  J Proteome Res       Date:  2017-07-27       Impact factor: 4.466

Review 5.  Functional architecture of Weibel-Palade bodies.

Authors:  Karine M Valentijn; J Evan Sadler; Jack A Valentijn; Jan Voorberg; Jeroen Eikenboom
Journal:  Blood       Date:  2011-01-25       Impact factor: 22.113

6.  Mutations in the D'D3 region of VWF traditionally associated with type 1 VWD lead to quantitative and qualitative deficiencies of VWF.

Authors:  Tara C White-Adams; Christopher J Ng; Paula M Jacobi; Sandra L Haberichter; Jorge A Di Paola
Journal:  Thromb Res       Date:  2016-08-10       Impact factor: 3.944

7.  Insights into pathological mechanisms of missense mutations in C-terminal domains of von Willebrand factor causing qualitative or quantitative von Willebrand disease.

Authors:  Hamideh Yadegari; Julia Driesen; Anna Pavlova; Arijit Biswas; Vytautas Ivaskevicius; Robert Klamroth; Johannes Oldenburg
Journal:  Haematologica       Date:  2013-03-28       Impact factor: 9.941

8.  Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.

Authors:  T Obser; M Ledford-Kraemer; F Oyen; M A Brehm; C V Denis; R Marschalek; R R Montgomery; J E Sadler; S Schneppenheim; U Budde; R Schneppenheim
Journal:  J Thromb Haemost       Date:  2016-08-20       Impact factor: 5.824

9.  Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort.

Authors:  Daniel J Hampshire; Adel M Abuzenadah; Ashley Cartwright; Nawal S Al-Shammari; Rachael E Coyle; Michaela Eckert; Ahlam M Al-Buhairan; Sarah L Messenger; Ulrich Budde; Türkiz Gürsel; Jørgen Ingerslev; Ian R Peake; Anne C Goodeve
Journal:  Thromb Haemost       Date:  2013-05-23       Impact factor: 5.249

10.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.